Clinical trials: CD160
Melanoma
Study of CD160, an Activating NK Cell Receptor, in Melanoma: a Potential Therapeutic Target?
Although immunotherapy revolutionized melanoma outcomes over the last 10 years, only 40-50% of patients respond to treatments and 25% develop acquired resistances.
- Trial name
- NKCD160MEL (NCT04477876)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris